[ad_1]
Digital Health for Epilepsy Company Positions for Future Growth with Closing of Latest Investment Round and Expansion of Board of Directors
BALTIMORE, April 7, 2022 /PRNewswire/ — EpiWatch, Inc., a digital health company focused on epilepsy, announced today the closing of its latest financing round and appointment of three new members to its Board of Directors.
The latest financing round will position the company to complete the clinical validation of its innovative tonic-clonic epileptic seizure detection and alerting software as a medical device to be offered initially on the Apple watch. Approximately 3.4 million people in the US have epilepsy, and 3,000 of those die each year from “Sudden Unexpected Death in Epilepsy” (SUDEP), the leading cause of death in people with uncontrolled epileptic seizures.
“We are pleased to have closed our latest financing round, adding talented and experienced experts to our Board of Directors. The combination of additional funding and expertise from our new directors will help galvanize our mission to bring to market digital health technologies which could substantially improve the lives of people with epilepsy and those who care for them,” said Dean PapadopoulosEpiWatch CEO.
Concurrent with the financing close, EpiWatch announced the following three additions to …
Full story available on Benzinga.com
[ad_2]
Source link
